Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 247

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 247
---
 chairperson of the nominating and corporate governance committee is entitled to receive additional annual                                                                                                                                    
 cash compensation in the amount of $9,000 per year for such chairperson’s service on the nominating and corporate governance committee. Each other member of the nominating and corporate governance committee is entitled to receive additional 
 annual cash compensation in the amount of $4,500 per year for such member’s service on the nominating and corporate governance committee.                                                                                                        |

Upon a non-employeedirector’s initial appointment or election to our board of directors, that person will receive an option (the “Initial Grant”) to purchase shares of our common stock with an aggregate grant date fair value as determined in accordance with U.S. generally accepted accounting principles equal to $106,000. The Initial Grant will vest as to one thirty-sixth (1/36) of the shares subject to the Initial Grant on a monthly basis following the Initial Grant’s grant date on the same day of the month as such grant date, subject to continued service through each applicable vesting date. In addition, each non-employeedirector who has been serving as a director for the prior six months and will continue to serve as a director immediately following each annual stockholder meeting, will receive, on the first trading day immediately following the date of such annual stockholder meeting, an option (the “Annual Grant”) to purchase shares of our common stock with an aggregate grant date fair value equal to $58,000. The Annual Grant will fully vest on the earlier of the first anniversary of the applicable grant date or the date immediately before the date of the next annual stockholder meeting, subject to continued service through such vesting date. In the event of a change in control, as defined in our 2021 Plan (or its successor plan, as applicable), each non-employeedirector’s then outstanding equity awards covering shares of our common stock will accelerate vesting in full, provided that he or she remains a non-employeedirector through the date of the closing of the change in control. Each Initial Grant and Annual Grant will be granted under our 2021 Plan (or its successor plan, as applicable) and form of award agreement under such plan. These awards will have a maximum term to expiration of 10 years from their grant and a per share exercise price equal to 100% of the fair market value of a share of our common stock on the award’s grant date. - 171 -

The 2021 Plan includes a maximum annual limit of $750,